Multiple Myeloma Kahler Disease-Pipeline Review, H1 2016

Multiple Myeloma Kahler Disease-Pipeline Review, H1 2016


  • Products Id :- GMDHC8160IDB
  • |
  • Pages: 1031
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Multiple Myeloma (Kahler Disease)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Multiple Myeloma (Kahler Disease)-Pipeline Review, H1 2016', provides an overview of the Multiple Myeloma (Kahler Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease)

The report reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Multiple Myeloma (Kahler Disease) therapeutics and enlists all their major and minor projects

The report assesses Multiple Myeloma (Kahler Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Multiple Myeloma (Kahler Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 9

Multiple Myeloma (Kahler Disease) Overview 10

Therapeutics Development 11

Multiple Myeloma (Kahler Disease)-Therapeutics under Development by Companies 13

Multiple Myeloma (Kahler Disease)-Therapeutics under Investigation by Universities/Institutes 26

Multiple Myeloma (Kahler Disease)-Pipeline Products Glance 28

Multiple Myeloma (Kahler Disease)-Products under Development by Companies 32

Multiple Myeloma (Kahler Disease)-Products under Investigation by Universities/Institutes 55

Multiple Myeloma (Kahler Disease)-Companies Involved in Therapeutics Development 58

Multiple Myeloma (Kahler Disease)-Therapeutics Assessment 201

Drug Profiles 252

Multiple Myeloma (Kahler Disease)-Dormant Projects 958

Multiple Myeloma (Kahler Disease)-Discontinued Products 982

Multiple Myeloma (Kahler Disease)-Product Development Milestones 987

Appendix 999

List of Figures

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016 42

Number of Products under Development for Multiple Myeloma (Kahler Disease)-Comparative Analysis, H1 2016 43

Number of Products under Development by Companies, H1 2016 44

Number of Products under Investigation by Universities/Institutes, H1 2016 57

Comparative Analysis by Late Stage Development, H1 2016 59

Comparative Analysis by Clinical Stage Development, H1 2016 60

Comparative Analysis by Early Stage Products, H1 2016 61

Assessment by Monotherapy Products, H1 2016 232

Assessment by Combination Products, H1 2016 233

Number of Products by Top 10 Targets, H1 2016 234

Number of Products by Stage and Top 10 Targets, H1 2016 234

Number of Products by Top 10 Mechanism of Actions, H1 2016 260

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 260

Number of Products by Top 10 Routes of Administration, H1 2016 279

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 279

Number of Products by Top 10 Molecule Types, H1 2016 281

Number of Products by Stage and Top 10 Molecule Types, H1 2016 281

List of Tables

Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2016 42

Number of Products under Development for Multiple Myeloma (Kahler Disease)-Comparative Analysis, H1 2016 43

Number of Products under Development by Companies, H1 2016 45

Number of Products under Development by Companies, H1 2016 (Contd..1) 46

Number of Products under Development by Companies, H1 2016 (Contd..2) 47

Number of Products under Development by Companies, H1 2016 (Contd..3) 48

Number of Products under Development by Companies, H1 2016 (Contd..4) 49

Number of Products under Development by Companies, H1 2016 (Contd..5) 50

Number of Products under Development by Companies, H1 2016 (Contd..6) 51

Number of Products under Development by Companies, H1 2016 (Contd..7) 52

Number of Products under Development by Companies, H1 2016 (Contd..8) 53

Number of Products under Development by Companies, H1 2016 (Contd..9) 54

Number of Products under Development by Companies, H1 2016 (Contd..10) 55

Number of Products under Development by Companies, H1 2016 (Contd..11) 56

Number of Products under Investigation by Universities/Institutes, H1 2016 57

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 58

Comparative Analysis by Late Stage Development, H1 2016 59

Comparative Analysis by Clinical Stage Development, H1 2016 60

Comparative Analysis by Early Stage Development, H1 2016 61

Comparative Analysis by Unknown Stage Development, H1 2016 62

Products under Development by Companies, H1 2016 63

Products under Development by Companies, H1 2016 (Contd..1) 64

Products under Development by Companies, H1 2016 (Contd..2) 65

Products under Development by Companies, H1 2016 (Contd..3) 66

Products under Development by Companies, H1 2016 (Contd..4) 67

Products under Development by Companies, H1 2016 (Contd..5) 68

Products under Development by Companies, H1 2016 (Contd..6) 69

Products under Development by Companies, H1 2016 (Contd..7) 70

Products under Development by Companies, H1 2016 (Contd..8) 71

Products under Development by Companies, H1 2016 (Contd..9) 72

Products under Development by Companies, H1 2016 (Contd..10) 73

Products under Development by Companies, H1 2016 (Contd..11) 74

Products under Development by Companies, H1 2016 (Contd..12) 75

Products under Development by Companies, H1 2016 (Contd..13) 76

Products under Development by Companies, H1 2016 (Contd..14) 77

Products under Development by Companies, H1 2016 (Contd..15) 78

Products under Development by Companies, H1 2016 (Contd..16) 79

Products under Development by Companies, H1 2016 (Contd..17) 80

Products under Development by Companies, H1 2016 (Contd..18) 81

Products under Development by Companies, H1 2016 (Contd..19) 82

Products under Development by Companies, H1 2016 (Contd..20) 83

Products under Development by Companies, H1 2016 (Contd..21) 84

Products under Development by Companies, H1 2016 (Contd..22) 85

Products under Investigation by Universities/Institutes, H1 2016 86

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 87

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 88

Multiple Myeloma (Kahler Disease)-Pipeline by 4SC AG, H1 2016 89

Multiple Myeloma (Kahler Disease)-Pipeline by AB Science SA, H1 2016 90

Multiple Myeloma (Kahler Disease)-Pipeline by AbbVie Inc., H1 2016 91

Multiple Myeloma (Kahler Disease)-Pipeline by Ablynx NV, H1 2016 92

Multiple Myeloma (Kahler Disease)-Pipeline by Acceleron Pharma, Inc., H1 2016 93

Multiple Myeloma (Kahler Disease)-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 94

Multiple Myeloma (Kahler Disease)-Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 95

Multiple Myeloma (Kahler Disease)-Pipeline by Active Biotech AB, H1 2016 96

Multiple Myeloma (Kahler Disease)-Pipeline by Adaptimmune Therapeutics Plc, H1 2016 97

Multiple Myeloma (Kahler Disease)-Pipeline by Aduro BioTech, Inc., H1 2016 98

Multiple Myeloma (Kahler Disease)-Pipeline by Affimed GmbH , H1 2016 99

Multiple Myeloma (Kahler Disease)-Pipeline by AIMM Therapeutics B.V., H1 2016 100

Multiple Myeloma (Kahler Disease)-Pipeline by Altor BioScience Corporation, H1 2016 101

Multiple Myeloma (Kahler Disease)-Pipeline by Amgen Inc., H1 2016 102

Multiple Myeloma (Kahler Disease)-Pipeline by Anthera Pharmaceuticals Inc., H1 2016 103

Multiple Myeloma (Kahler Disease)-Pipeline by APIM Therapeutics AS, H1 2016 104

Multiple Myeloma (Kahler Disease)-Pipeline by APO-T B.V., H1 2016 105

Multiple Myeloma (Kahler Disease)-Pipeline by Arcarios BV, H1 2016 106

Multiple Myeloma (Kahler Disease)-Pipeline by Arno Therapeutics, Inc., H1 2016 107

Multiple Myeloma (Kahler Disease)-Pipeline by Array BioPharma Inc., H1 2016 108

Multiple Myeloma (Kahler Disease)-Pipeline by Arvinas, Inc., H1 2016 109

Multiple Myeloma (Kahler Disease)-Pipeline by Asana BioSciences, LLC, H1 2016 110

Multiple Myeloma (Kahler Disease)-Pipeline by Astellas Pharma Inc., H1 2016 111

Multiple Myeloma (Kahler Disease)-Pipeline by Astex Pharmaceuticals, Inc., H1 2016 112

Multiple Myeloma (Kahler Disease)-Pipeline by Atara Biotherapeutics, Inc., H1 2016 113

Multiple Myeloma (Kahler Disease)-Pipeline by Aurigene Discovery Technologies Limited, H1 2016 114

Multiple Myeloma (Kahler Disease)-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 115

Multiple Myeloma (Kahler Disease)-Pipeline by BioInvent International AB, H1 2016 116

Multiple Myeloma (Kahler Disease)-Pipeline by Biotest AG, H1 2016 117

Multiple Myeloma (Kahler Disease)-Pipeline by bluebird bio, Inc., H1 2016 118

Multiple Myeloma (Kahler Disease)-Pipeline by Boehringer Ingelheim GmbH, H1 2016 119

Multiple Myeloma (Kahler Disease)-Pipeline by Boston Biomedical, Inc., H1 2016 120

Multiple Myeloma (Kahler Disease)-Pipeline by Bristol-Myers Squibb Company, H1 2016 121

Multiple Myeloma (Kahler Disease)-Pipeline by Calithera Biosciences, Inc., H1 2016 122

Multiple Myeloma (Kahler Disease)-Pipeline by Celgene Corporation, H1 2016 123

Multiple Myeloma (Kahler Disease)-Pipeline by Cell Source, Inc., H1 2016 124

Multiple Myeloma (Kahler Disease)-Pipeline by Cellectar Biosciences, Inc., H1 2016 125

Multiple Myeloma (Kahler Disease)-Pipeline by Cellectis S.A., H1 2016 126

Multiple Myeloma (Kahler Disease)-Pipeline by Cellerant Therapeutics, Inc., H1 2016 127

Multiple Myeloma (Kahler Disease)-Pipeline by Celleron Therapeutics Limited, H1 2016 128

Multiple Myeloma (Kahler Disease)-Pipeline by Celyad SA, H1 2016 129

Multiple Myeloma (Kahler Disease)-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 130

Multiple Myeloma (Kahler Disease)-Pipeline by Cleave Biosciences, H1 2016 131

Multiple Myeloma (Kahler Disease)-Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 132

Multiple Myeloma (Kahler Disease)-Pipeline by ConverGene, LLC, H1 2016 133

Multiple Myeloma (Kahler Disease)-Pipeline by Curis, Inc., H1 2016 134

Multiple Myeloma (Kahler Disease)-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 135

Multiple Myeloma (Kahler Disease)-Pipeline by Daiichi Sankyo Company, Limited, H1 2016 136

Multiple Myeloma (Kahler Disease)-Pipeline by DC Prime B.V., H1 2016 137

Multiple Myeloma (Kahler Disease)-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 138

Multiple Myeloma (Kahler Disease)-Pipeline by Eli Lilly and Company, H1 2016 139

Multiple Myeloma (Kahler Disease)-Pipeline by Enceladus Pharmaceuticals BV, H1 2016 140

Multiple Myeloma (Kahler Disease)-Pipeline by Exelixis, Inc., H1 2016 141

Multiple Myeloma (Kahler Disease)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 142

Multiple Myeloma (Kahler Disease)-Pipeline by Gamida Cell Ltd., H1 2016 143

Multiple Myeloma (Kahler Disease)-Pipeline by Genenta Science s.r.l., H1 2016 144

Multiple Myeloma (Kahler Disease)-Pipeline by GlaxoSmithKline Plc, H1 2016 145

Multiple Myeloma (Kahler Disease)-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 146

Multiple Myeloma (Kahler Disease)-Pipeline by Gliknik, Inc., H1 2016 147

Multiple Myeloma (Kahler Disease)-Pipeline by GlycoMimetics, Inc., H1 2016 148

Multiple Myeloma (Kahler Disease)-Pipeline by Heidelberg Pharma GmbH, H1 2016 149

Multiple Myeloma (Kahler Disease)-Pipeline by Hutchison MediPharma Limited, H1 2016 150

Multiple Myeloma (Kahler Disease)-Pipeline by IGF Oncology, LLC., H1 2016 151

Multiple Myeloma (Kahler Disease)-Pipeline by ImmunGene, Inc., H1 2016 152

Multiple Myeloma (Kahler Disease)-Pipeline by Immunocore Limited, H1 2016 153

Multiple Myeloma (Kahler Disease)-Pipeline by Immunomic Therapeutics, Inc., H1 2016 154

Multiple Myeloma (Kahler Disease)-Pipeline by Incyte Corporation, H1 2016 155

Multiple Myeloma (Kahler Disease)-Pipeline by Inflection Biosciences Limited, H1 2016 156

Multiple Myeloma (Kahler Disease)-Pipeline by Inventiva, H1 2016 157

Multiple Myeloma (Kahler Disease)-Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 158

Multiple Myeloma (Kahler Disease)-Pipeline by Johnson & Johnson, H1 2016 159

Multiple Myeloma (Kahler Disease)-Pipeline by JW Pharmaceutical Corporation, H1 2016 160

Multiple Myeloma (Kahler Disease)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 161

Multiple Myeloma (Kahler Disease)-Pipeline by Kancer Limited, H1 2016 162

Multiple Myeloma (Kahler Disease)-Pipeline by Kancera AB, H1 2016 163

Multiple Myeloma (Kahler Disease)-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 164

Multiple Myeloma (Kahler Disease)-Pipeline by Kezar Life Sciences, Inc., H1 2016 165

Multiple Myeloma (Kahler Disease)-Pipeline by LG Life Science LTD., H1 2016 166

Multiple Myeloma (Kahler Disease)-Pipeline by MedImmune, LLC, H1 2016 167

Multiple Myeloma (Kahler Disease)-Pipeline by Medivation, Inc., H1 2016 168

Multiple Myeloma (Kahler Disease)-Pipeline by Merck & Co., Inc., H1 2016 169

Multiple Myeloma (Kahler Disease)-Pipeline by Midatech Pharma US Inc., H1 2016 170

Multiple Myeloma (Kahler Disease)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 171

Multiple Myeloma (Kahler Disease)-Pipeline by MimiVax, LLC, H1 2016 172

Multiple Myeloma (Kahler Disease)-Pipeline by Mirna Therapeutics, Inc., H1 2016 173

Multiple Myeloma (Kahler Disease)-Pipeline by Molecular Partners AG, H1 2016 174

Multiple Myeloma (Kahler Disease)-Pipeline by Molecular Templates Inc., H1 2016 175

Multiple Myeloma (Kahler Disease)-Pipeline by MolMed S.p.A., H1 2016 176

Multiple Myeloma (Kahler Disease)-Pipeline by MorphoSys AG, H1 2016 177

Multiple Myeloma (Kahler Disease)-Pipeline by NantKwest, Inc., H1 2016 178

Multiple Myeloma (Kahler Disease)-Pipeline by Nippon Kayaku Co., Ltd., H1 2016 179

Multiple Myeloma (Kahler Disease)-Pipeline by Nordic Nanovector ASA, H1 2016 180

Multiple Myeloma (Kahler Disease)-Pipeline by Novartis AG, H1 2016 181

Multiple Myeloma (Kahler Disease)-Pipeline by Noxxon Pharma AG, H1 2016 182

Multiple Myeloma (Kahler Disease)-Pipeline by Oncodesign SA, H1 2016 183

Multiple Myeloma (Kahler Disease)-Pipeline by Oncolytics Biotech Inc., H1 2016 184

Multiple Myeloma (Kahler Disease)-Pipeline by Onconova Therapeutics, Inc., H1 2016 185

Multiple Myeloma (Kahler Disease)-Pipeline by OncoPep Inc., H1 2016 186

Multiple Myeloma (Kahler Disease)-Pipeline by Oncopeptides AB, H1 2016 187

Multiple Myeloma (Kahler Disease)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 188

Multiple Myeloma (Kahler Disease)-Pipeline by OXIS International, Inc., H1 2016 189

Multiple Myeloma (Kahler Disease)-Pipeline by Peptinov SAS, H1 2016 190

Multiple Myeloma (Kahler Disease)-Pipeline by Pfizer Inc., H1 2016 191

Multiple Myeloma (Kahler Disease)-Pipeline by Pharma Mar, S.A., H1 2016 192

Multiple Myeloma (Kahler Disease)-Pipeline by Phylogica Limited, H1 2016 193

Multiple Myeloma (Kahler Disease)-Pipeline by Polyphor Ltd., H1 2016 194

Multiple Myeloma (Kahler Disease)-Pipeline by Prescient Therapeutics Limited, H1 2016 195

Multiple Myeloma (Kahler Disease)-Pipeline by Progenra, Inc., H1 2016 196

Multiple Myeloma (Kahler Disease)-Pipeline by Quest PharmaTech Inc., H1 2016 197

Multiple Myeloma (Kahler Disease)-Pipeline by Quimatryx, S.L., H1 2016 198

Multiple Myeloma (Kahler Disease)-Pipeline by RedHill Biopharma Ltd., H1 2016 199

Multiple Myeloma (Kahler Disease)-Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 200

Multiple Myeloma (Kahler Disease)-Pipeline by Rodos BioTarget GmbH, H1 2016 201

Multiple Myeloma (Kahler Disease)-Pipeline by Sanofi, H1 2016 202

Multiple Myeloma (Kahler Disease)-Pipeline by Seattle Genetics, Inc., H1 2016 203

Multiple Myeloma (Kahler Disease)-Pipeline by Selexys Pharmaceuticals Corporation, H1 2016 204

Multiple Myeloma (Kahler Disease)-Pipeline by Sellas Inc., H1 2016 205

Multiple Myeloma (Kahler Disease)-Pipeline by Selvita S.A., H1 2016 206

Multiple Myeloma (Kahler Disease)-Pipeline by Senhwa Biosciences, Inc., H1 2016 207

Multiple Myeloma (Kahler Disease)-Pipeline by Sigma-Tau S.p.A., H1 2016 208

Multiple Myeloma (Kahler Disease)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 209

Multiple Myeloma (Kahler Disease)-Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 210

Multiple Myeloma (Kahler Disease)-Pipeline by Stemline Therapeutics, Inc., H1 2016 211

Multiple Myeloma (Kahler Disease)-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 212

Multiple Myeloma (Kahler Disease)-Pipeline by Synta Pharmaceuticals Corp., H1 2016 213

Multiple Myeloma (Kahler Disease)-Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 214

Multiple Myeloma (Kahler Disease)-Pipeline by TaiRx, Inc., H1 2016 215

Multiple Myeloma (Kahler Disease)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 216

Multiple Myeloma (Kahler Disease)-Pipeline by Targazyme, Inc., H1 2016 217

Multiple Myeloma (Kahler Disease)-Pipeline by Terpenoid Therapeutics, Inc., H1 2016 218

Multiple Myeloma (Kahler Disease)-Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 219

Multiple Myeloma (Kahler Disease)-Pipeline by TG Therapeutics, Inc., H1 2016 220

Multiple Myeloma (Kahler Disease)-Pipeline by Theravectys SA, H1 2016 221

Multiple Myeloma (Kahler Disease)-Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 222

Multiple Myeloma (Kahler Disease)-Pipeline by Transgene Biotek Limited, H1 2016 223

Multiple Myeloma (Kahler Disease)-Pipeline by Trillium Therapeutics Inc., H1 2016 224

Multiple Myeloma (Kahler Disease)-Pipeline by Vaccibody AS, H1 2016 225

Multiple Myeloma (Kahler Disease)-Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016 226

Multiple Myeloma (Kahler Disease)-Pipeline by Verastem, Inc., H1 2016 227

Multiple Myeloma (Kahler Disease)-Pipeline by Vichem Chemie Research Ltd., H1 2016 228

Multiple Myeloma (Kahler Disease)-Pipeline by Vivolux AB, H1 2016 229

Multiple Myeloma (Kahler Disease)-Pipeline by Vyriad, H1 2016 230

Multiple Myeloma (Kahler Disease)-Pipeline by XTL Biopharmaceuticals Ltd., H1 2016 231

Assessment by Monotherapy Products, H1 2016 232

Assessment by Combination Products, H1 2016 233

Number of Products by Stage and Target, H1 2016 235

Number of Products by Stage and Mechanism of Action, H1 2016 261

Number of Products by Stage and Route of Administration, H1 2016 280

Number of Products by Stage and Molecule Type, H1 2016 282

Multiple Myeloma (Kahler Disease)-Dormant Projects, H1 2016 989

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..1), H1 2016 990

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..2), H1 2016 991

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..3), H1 2016 992

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..4), H1 2016 993

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..5), H1 2016 994

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..6), H1 2016 995

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..7), H1 2016 996

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..8), H1 2016 997

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..9), H1 2016 998

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..10), H1 2016 999

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..11), H1 2016 1000

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..12), H1 2016 1001

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..13), H1 2016 1002

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..14), H1 2016 1003

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..15), H1 2016 1004

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..16), H1 2016 1005

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..17), H1 2016 1006

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..18), H1 2016 1007

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..19), H1 2016 1008

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..20), H1 2016 1009

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..21), H1 2016 1010

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..22), H1 2016 1011

Multiple Myeloma (Kahler Disease)-Dormant Projects (Contd..23), H1 2016 1012

Multiple Myeloma (Kahler Disease)-Discontinued Products, H1 2016 1013

Multiple Myeloma (Kahler Disease)-Discontinued Products (Contd..1), H1 2016 1014

Multiple Myeloma (Kahler Disease)-Discontinued Products (Contd..2), H1 2016 1015

Multiple Myeloma (Kahler Disease)-Discontinued Products (Contd..3), H1 2016 1016

Multiple Myeloma (Kahler Disease)-Discontinued Products (Contd..4), H1 2016 1017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science SA

AbbVie Inc.

Ablynx NV

Acceleron Pharma, Inc.

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Active Biotech AB

Adaptimmune Therapeutics Plc

Aduro BioTech, Inc.

Affimed GmbH

AIMM Therapeutics B.V.

Altor BioScience Corporation

Amgen Inc.

Anthera Pharmaceuticals Inc.

APIM Therapeutics AS

APO-T B.V.

Arcarios BV

Arno Therapeutics, Inc.

Array BioPharma Inc.

Arvinas, Inc.

Asana BioSciences, LLC

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Atara Biotherapeutics, Inc.

Aurigene Discovery Technologies Limited

Bellicum Pharmaceuticals, Inc.

BioInvent International AB

Biotest AG

bluebird bio, Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Celgene Corporation

Cell Source, Inc.

Cellectar Biosciences, Inc.

Cellectis S.A.

Cellerant Therapeutics, Inc.

Celleron Therapeutics Limited

Celyad SA

Chong Kun Dang Pharmaceutical Corp.

Cleave Biosciences

Constellation Pharmaceuticals, Inc.

ConverGene, LLC

Curis, Inc.

Cyclacel Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

DC Prime B.V.

Dicerna Pharmaceuticals, Inc.

Eli Lilly and Company

Enceladus Pharmaceuticals BV

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Gamida Cell Ltd.

Genenta Science s.r.l.

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

Gliknik, Inc.

GlycoMimetics, Inc.

Heidelberg Pharma GmbH

Hutchison MediPharma Limited

IGF Oncology, LLC.

ImmunGene, Inc.

Immunocore Limited

Immunomic Therapeutics, Inc.

Incyte Corporation

Inflection Biosciences Limited

Inventiva

Jasco Pharmaceuticals, LLC.

Johnson & Johnson

JW Pharmaceutical Corporation

KaloBios Pharmaceuticals, Inc.

Kancer Limited

Kancera AB

Karyopharm Therapeutics, Inc.

Kezar Life Sciences, Inc.

LG Life Science LTD.

MedImmune, LLC

Medivation, Inc.

Merck & Co., Inc.

Midatech Pharma US Inc.

Millennium Pharmaceuticals, Inc.

MimiVax, LLC

Mirna Therapeutics, Inc.

Molecular Partners AG

Molecular Templates Inc.

MolMed S.p.A.

MorphoSys AG

NantKwest, Inc.

Nippon Kayaku Co., Ltd.

Nordic Nanovector ASA

Novartis AG

Noxxon Pharma AG

Oncodesign SA

Oncolytics Biotech Inc.

Onconova Therapeutics, Inc.

OncoPep Inc.

Oncopeptides AB

Ono Pharmaceutical Co., Ltd.

OXIS International, Inc.

Peptinov SAS

Pfizer Inc.

Pharma Mar, S.A.

Phylogica Limited

Polyphor Ltd.

Prescient Therapeutics Limited

Progenra, Inc.

Quest PharmaTech Inc.

Quimatryx, S.L.

RedHill Biopharma Ltd.

Rhizen Pharmaceuticals S.A.

Rodos BioTarget GmbH

Sanofi

Seattle Genetics, Inc.

Selexys Pharmaceuticals Corporation

Sellas Inc.

Selvita S.A.

Senhwa Biosciences, Inc.

Sigma-Tau S.p.A.

Spectrum Pharmaceuticals, Inc.

Sphaera Pharma Pvt. Ltd.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synta Pharmaceuticals Corp.

Taiho Pharmaceutical Co., Ltd.

TaiRx, Inc.

Takeda Pharmaceutical Company Limited

Targazyme, Inc.

Terpenoid Therapeutics, Inc.

Teva Pharmaceutical Industries Ltd.

TG Therapeutics, Inc.

Theravectys SA

Tragara Pharmaceuticals, Inc.

Transgene Biotek Limited

Trillium Therapeutics Inc.

Vaccibody AS

Vaxil Bio Therapeutics Ltd.

Verastem, Inc.

Vichem Chemie Research Ltd.

Vivolux AB

Vyriad

XTL Biopharmaceuticals Ltd.

Multiple Myeloma (Kahler Disease) Therapeutic Products under Development, Key Players in Multiple Myeloma (Kahler Disease) Therapeutics, Multiple Myeloma (Kahler Disease) Pipeline Overview, Multiple Myeloma (Kahler Disease) Pipeline, Multiple Myeloma (Kahler Disease) Pipeline Assessment

select a license

Single User License
USD 2500 INR 161450
Site License
USD 5000 INR 322900
Corporate User License
USD 7500 INR 484350

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com